HealthBio, Inc., a biotechnology company developing novel immune-reset therapies for inflammatory disease, today announced the initiation of its multi-center, randomized, double-blind, ...

Immune thrombocytopenia (ITP) is a disorder of increased platelet destruction and reduced platelet production and is associated with an increased bleeding risk and a compromised quality of life.

XALience: A phase 3, open-label, multicenter, randomized study of xaluritamig plus abiraterone vs investigator’s choice in patients with chemotherapy-naïve metastatic castration-resistant prostate ...

Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of neoantigen-based personalized immunotherapy for cancer (PIC), today announced the initiation of its Phase 2 ...

A phase 2 trial of androgen deprivation therapy interruption in patients responding exceptionally to androgen receptor pathway inhibitor in metastatic hormone-sensitive prostate cancer (A-DREAM / ...

Since the interim data cut reported in the accepted manuscript, CAMPX has completed patient enrollment and Last Patient, Last ...

A planned randomized trial in Germany will compare standard care with a 14-week interprofessional outpatient program for 540 ...

A pilot randomized trial found that internal medicine residents who practiced code status discussions with an AI chatbot ...